QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
NASDAQ:TVTX

Travere Therapeutics - TVTX Stock Forecast, Price & News

$22.40
+0.97 (+4.53%)
(As of 01/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$21.47
$22.56
50-Day Range
$18.47
$21.88
52-Week Range
$17.97
$30.35
Volume
1.16 million shs
Average Volume
1.09 million shs
Market Capitalization
$1.44 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.44

Travere Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
43.8% Upside
$32.22 Price Target
Short Interest
Healthy
11.72% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.35mentions of Travere Therapeutics in the last 14 days
Based on 23 Articles This Week
Insider Trading
Selling Shares
$414,536 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.38) to ($3.80) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

789th out of 1,055 stocks

Pharmaceutical Preparations Industry

394th out of 518 stocks


TVTX stock logo

About Travere Therapeutics (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Receive TVTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TVTX Stock News Headlines

The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Recap: Travere Therapeutics Q3 Earnings
Earnings Outlook For Travere Therapeutics
What 4 Analyst Ratings Have To Say About Travere Therapeutics
Expert Ratings for Travere Therapeutics
See More Headlines
Receive TVTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TVTX Company Calendar

Last Earnings
10/28/2021
Today
1/31/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TVTX
Employees
310
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$32.22
High Stock Price Forecast
$42.00
Low Stock Price Forecast
$17.00
Forecasted Upside/Downside
+44.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-180,090,000.00
Net Margins
-123.82%
Pretax Margin
-123.70%

Debt

Sales & Book Value

Annual Sales
$227.49 million
Book Value
$4.93 per share

Miscellaneous

Free Float
61,151,000
Market Cap
$1.44 billion
Optionable
Optionable
Beta
0.48

Key Executives

  • Dr. Eric M. Dube Ph.D. (Age 50)
    Pres, CEO & Director
    Comp: $1.27M
  • Ms. Elizabeth E. ReedMs. Elizabeth E. Reed (Age 52)
    Sr. VP, Gen. Counsel & Corp. Sec.
    Comp: $696.68k
  • Dr. William E. Rote Ph.D. (Age 60)
    Sr. VP of R&D
    Comp: $752.35k
  • Mr. Christopher Cline C.F.A. (Age 39)
    CFA, Chief Financial Officer
  • Ms. Sandra CalvinMs. Sandra Calvin (Age 58)
    VP, Corp. Controller & Principal Accounting Officer
  • Ms. Charlotte Smith
    Sr. VP of Public Affairs
  • Mr. Casey Logan
    Sr. VP of Corp. & Bus. Devel.
  • Ms. Angela Giannantonio
    Sr. VP of HR
  • Mr. Peter HeermaMr. Peter Heerma (Age 52)
    Chief Commercial Officer
  • Dr. Jula Inrig M.D. (Age 48)
    Chief Medical Officer













TVTX Stock - Frequently Asked Questions

Should I buy or sell Travere Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Travere Therapeutics in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TVTX shares.
View TVTX analyst ratings
or view top-rated stocks.

What is Travere Therapeutics' stock price forecast for 2023?

7 analysts have issued 12-month price targets for Travere Therapeutics' shares. Their TVTX share price forecasts range from $17.00 to $42.00. On average, they anticipate the company's share price to reach $32.22 in the next twelve months. This suggests a possible upside of 47.1% from the stock's current price.
View analysts price targets for TVTX
or view top-rated stocks among Wall Street analysts.

How have TVTX shares performed in 2023?

Travere Therapeutics' stock was trading at $21.03 at the beginning of the year. Since then, TVTX shares have increased by 4.2% and is now trading at $21.91.
View the best growth stocks for 2023 here
.

When is Travere Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our TVTX earnings forecast
.

How were Travere Therapeutics' earnings last quarter?

Travere Therapeutics, Inc. (NASDAQ:TVTX) announced its earnings results on Thursday, October, 28th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.13. The company earned $68.20 million during the quarter, compared to analyst estimates of $60.93 million. Travere Therapeutics had a negative trailing twelve-month return on equity of 137.68% and a negative net margin of 123.82%. The company's revenue was up 33.5% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.44) EPS.

What guidance has Travere Therapeutics issued on next quarter's earnings?

Travere Therapeutics updated its FY 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $212.00 million-$212.00 million, compared to the consensus revenue estimate of $212.08 million.

What is Travere Therapeutics' stock symbol?

Travere Therapeutics trades on the NASDAQ under the ticker symbol "TVTX."

Who are Travere Therapeutics' major shareholders?

Travere Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (1.35%), National Bank of Canada FI (0.18%), Oak Ridge Investments LLC (0.13%), Rice Hall James & Associates LLC (0.12%), Hennion & Walsh Asset Management Inc. (0.12%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Christopher R Cline, Elizabeth E Reed, Eric M Dube, Jula Inrig, Laura Clague, Noah L Rosenberg, Noah L Rosenberg, Peter Heerma, Sandra Calvin, Steve Aselage and William E Rote.
View institutional ownership trends
.

How do I buy shares of Travere Therapeutics?

Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Travere Therapeutics' stock price today?

One share of TVTX stock can currently be purchased for approximately $21.91.

How much money does Travere Therapeutics make?

Travere Therapeutics (NASDAQ:TVTX) has a market capitalization of $1.41 billion and generates $227.49 million in revenue each year. The company earns $-180,090,000.00 in net income (profit) each year or ($4.18) on an earnings per share basis.

How many employees does Travere Therapeutics have?

The company employs 310 workers across the globe.

How can I contact Travere Therapeutics?

Travere Therapeutics' mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The official website for the company is www.retrophin.com. The company can be reached via phone at (888) 969-7879, via email at ir@retrophin.com, or via fax at 302-645-1280.

This page (NASDAQ:TVTX) was last updated on 1/31/2023 by MarketBeat.com Staff